Editorial Comment

Abstract

This report by Brant et al. adds to the growing body of evidence in support of opioid sparing prostatectomies. In this population-based analysis of The Premier Hospital Database, the authors demonstrate that almost a quarter of prostatectomies performed between 2015 and 2020 were “opioid-sparing” (i.e., no intravenous opioids after post-operative day zero and no oral opioids throughout admission). Ketorolac utilization during the perioperative period was associated with 86% increased odds of an opioid-sparing procedure without increased risks of post-operative bleeding (0.3%) or dialysis requirement (<0.1%).